# Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

> **NCT03973047** · PHASE1 · COMPLETED · sponsor: **AMAG Pharmaceuticals, Inc.** · enrollment: 228 (actual)

## Conditions studied

- Nausea

## Interventions

- **DRUG:** Bremelanotide
- **DRUG:** Zofran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03973047
- **Lead sponsor:** AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2019-07-19
- **Final completion:** 2019-07-20
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03973047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03973047, "Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03973047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*